Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Gelmetix logo — We focus on the treatment of chronic lower back pain caused...

Gelmetix

We focus on the treatment of chronic lower back pain caused by the degeneration of intervertebral discs

Founded 2012 United Kingdom London, United Kingdom 9 employees Series C Total: $10.25M Biotechnology, Health Care +1

General Information

Company Name Gelmetix
Founded Year 2012
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 9
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Gelmetix. To contact Gelmetix, visit gelmetix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Gelmetix compare?

A PDF of Gelmetix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Gelmetix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Gelmetix

Gelmetix is a biotech startup based in the United Kingdom, focusing on the treatment of chronic lower back pain caused by the degeneration of intervertebral discs. Founded in 2012 as a spin-off from the University of Manchester, Gelmetix has gained recognition for its innovative approach. The company's patented polymer gel technology offers an efficient, cost-effective, and drug-free solution for preventing pain and restoring functionality and movement in patients. This technology, which has been highlighted as a promising innovation in the biotech industry, works by rehydrating and stabilizing intervertebral discs, thereby restoring their natural integrity. Gelmetix's recent achievement was securing a noteworthy £5.00M Series C investment on 14 May 2021, with participation from Wealth Club, Jonathan Milner, and Seneca Partners. This investment signifies the confidence that notable investors have in Gelmetix's potential to address a critical medical need and create impactful solutions in the field of biotechnology and healthcare.

Business keywords: Chronic Lower Back Pain Treatment, Intervertebral Disc Degeneration, Polymer Gel Technology, Non-Drug Therapy, Patented Medical Technology, Spin-off from University of Manchester, Biotech Start-up, EIT Health Catapult, Degenerative Disc Disease, Pain Management, Functional Restoration, Medical Innovation

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C £5.00M 3
Seneca Partners
Seneca Partners, Wealth Club +1
14 May 2021
Series B £1.20M 3
University of Manchester, Jonathan Milner +1
01 Sep 2018
Series A £3.10M 1
The North West Fund
The North West Fund
01 Jan 2016
Venture Round £950.00K 2
The North West Fund
The North West Fund, University of Manchester
01 Jan 2014

Gelmetix Alternatives & Competitors

View All Alternatives
Gelmetix vs
Notogen Inc.
Notogen Inc. Canada

Developing a disease-modifying regenerative therapy for degenerative disc disease

5 employees
Biotechnology, Health Care
Gelmetix vs
AVACEN Medical
AVACEN Medical United States

Pain Relief from the Palm of Your Hand

Equity Crowdfunding
44 employees
Health Care, Health and Wellness
Gelmetix vs
NIQS Tech
NIQS Tech United Kingdom

Glucose Insights, Smarter Living

Seed
4 employees
Health Care, Medical Devices
View all alternatives

FAQ About Gelmetix

We focus on the treatment of chronic lower back pain caused by the degeneration of intervertebral discs
Gelmetix was founded in 2012.
Gelmetix is headquartered in London, United Kingdom.
Gelmetix operates in Biotechnology, Health Care and Medical Devices. Its work centres on Chronic Lower Back Pain Treatment, Intervertebral Disc Degeneration, Polymer Gel Technology and Non-Drug Therapy.
Gelmetix has approximately 9 employees.
Gelmetix has completed 4 funding rounds, raising a total of $10.25M. The latest funding stage is Series C.
Top alternatives and competitors to Gelmetix include Notogen Inc., AVACEN Medical, NIQS Tech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gelmetix and Notogen Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Gelmetix, https://bouncewatch.com/company/gelmetix, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes